A Randomized Phase II Study of Eribulin/Cyclophosphamide or Docetaxel/Cyclophosphamide as Neoadjuvant Therapy in Operable HER2-negative Breast Cancer

Denise A. Yardley, Dianna Shipley, John Zubkus, Gail L. Wright, Patrick J. Ward, Aruna Mani, Mythili Shastry, Lindsey Finney, Laura DeBusk, John D. Hainsworth

Research output: Contribution to journalArticle

3 Scopus citations

Fingerprint Dive into the research topics of 'A Randomized Phase II Study of Eribulin/Cyclophosphamide or Docetaxel/Cyclophosphamide as Neoadjuvant Therapy in Operable HER2-negative Breast Cancer'. Together they form a unique fingerprint.

Medicine & Life Sciences